Ivan Kairatov is a leading biopharma expert with a deep specialization in the intersection of oncology and innovative research and development. With years of experience navigating the complexities of the drug development pipeline and cellular biotechnology, he offers a unique perspective on the early-stage molecular drivers of disease. In this conversation, we explore groundbreaking research from the Hebrew University of Jerusalem regarding the spatial organization of precancerous pancreatic cells and how these early clusters manipulate the immune system to ensure their survival long before clinical symptoms emerge.
Precancerous cells in the pancreas tend to form organized “neighborhoods” rather than spreading randomly. How do these clusters establish their spatial boundaries, and what specific molecular signals allow them to recruit nearby immune cells into these distinct niches?
The establishment of these “neighborhoods” is a fascinating display of cellular coordination that contradicts the old idea of random mutations leading to chaotic growth. Our research indicates that acinar metaplastic cells, which are the precursors to malignancy, do not drift apart; instead, cells with identical identities actively seek each other out to form semi-homogeneous niches. These boundaries are likely maintained through localized expansion and specific signaling pathways that define the edge of the lesion against healthy tissue. Once these clusters are established, they begin emitting molecular signals—identified through single-cell RNA sequencing—that act as a beacon for immune cells. By concentrating these signals within a tight spatial context, the precancerous cells effectively “recruit” immune partners into their immediate vicinity, creating a private microenvironment where they can develop undisturbed.
Early metaplastic cells appear to interact with neutrophils and macrophages to create an immunosuppressive environment. Could you walk us through the step-by-step mechanism of this communication and explain how these interactions effectively “blind” the immune system years before a tumor becomes invasive?
The process of “blinding” the immune system is a sophisticated, multi-step communication strategy that begins a decade or more before a tumor is even detectable. First, the metaplastic cells express gene patterns that are specifically designed to communicate with subsets of neutrophils and macrophages. When these immune cells enter the niche, the metaplastic cells deliver signals that reprogram them from their natural “attack” mode into a suppressive state. We observed that these interactions lead to the dampening of local immune activity, essentially turning the body’s defenders into silent bystanders or even active protectors of the lesion. This early-stage immunosuppression creates a “cold” environment where the immune system simply fails to recognize the burgeoning cancer as a threat, allowing the cells to evolve in total secrecy for years.
Mapping the precise location and gene expression of individual cells requires sophisticated spatial transcriptomics and RNA sequencing. What are the primary technical hurdles when applying these tools to human pancreatic tissue, and what metrics best indicate a successful mapping of a premalignant lesion?
One of the most significant hurdles in mapping these lesions is preserving the spatial context while trying to extract high-quality genetic data from thousands of individual cells. In pancreatic tissue, which is rich in enzymes that can quickly degrade RNA, the technical challenge is to capture the “snapshot” of the tissue without losing the delicate links between cell location and gene expression. We consider a mapping successful when we can identify distinct spatial patterns where specific metaplastic cell states consistently align with specific immune cell populations. Measuring the density of these interactions and the consistency of gene expression across thousands of cells provides the metric for a high-fidelity map. By successfully maintaining this spatial architecture, we can see exactly how the “neighborhood” is built, rather than just looking at a scrambled list of present cell types.
If immune evasion begins a decade or more before clinical symptoms appear, the window for medical intervention is significant. What specific biomarkers within these early cell clusters show the most promise for screening, and how might a future treatment strategy disrupt these clusters before they evolve?
The most promising biomarkers are those linked to the specific immunosuppressive signals and gene expression patterns found in the acinar metaplastic cells. Because these signals appear so early, they offer a unique “molecular fingerprint” that could be used for high-sensitivity screening in high-risk patients. A future treatment strategy wouldn’t just focus on killing the precancerous cells, but rather on disrupting the “neighborhood” they have built. By blocking the communication lines between these cells and the recruited neutrophils or macrophages, we could potentially prevent the formation of the immunosuppressive niche. This would leave the precancerous cells exposed to the body’s natural immune defenses, essentially stripping away their “cloaking device” before they ever have the chance to become invasive.
Cellular organizations found in animal models do not always translate perfectly to human biology. Since similar spatial patterns have been observed in human pancreatic samples, what are the key similarities in immune response between the two, and how does this overlap change the approach to early-stage drug testing?
The discovery that human pancreatic samples mirror the spatial organization and immune interactions seen in our models is a major milestone for translational medicine. In both cases, we see the same clustering of metaplastic cells and the same recruitment of suppressive immune subsets, which confirms that the “neighborhood” strategy is a fundamental part of the disease’s biology. This overlap means we can be much more confident when moving from the lab to clinical applications, as the fundamental mechanisms of immune evasion appear to be conserved across species. For drug testing, this allows us to target specific interaction pathways with the knowledge that these mechanisms are active in human patients years before diagnosis. It shifts our focus toward therapies that can modulate the immune microenvironment very early in the disease’s progression.
What is your forecast for the future of pancreatic cancer early detection?
My forecast is that we are moving toward a paradigm where pancreatic cancer is managed as a preventable condition rather than a late-stage emergency. Within the next decade, I expect we will utilize spatial transcriptomics-derived biomarkers to identify high-risk lesions during routine screenings, long before they turn invasive. By focusing on the “immunosuppressive niches” we’ve discovered, clinicians will be able to deploy targeted interventions that reset the local immune environment. This transition from “detecting the tumor” to “detecting the environment that allows the tumor” will drastically improve survival rates. Ultimately, we will stop trying to catch the fire after it has spread and start identifying the smoldering embers within these cellular neighborhoods.
